These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 10360735)

  • 1. Low-molecular-weight anti-HIV-1 peptides from the amino-terminal sequence of RANTES: possible lead compounds for coreceptor-directed anti-HIV-1 agents.
    Nishiyama Y; Murakami T; Kurita K; Yamamoto N
    Bioorg Med Chem Lett; 1999 May; 9(10):1357-60. PubMed ID: 10360735
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis of some peptides corresponding to the active region of RANTES for chemotaxis and evaluation of their anti-human immunodeficiency virus-1 activity.
    Nishiyama Y; Murakami T; Kurita K; Yamamoto N
    Chem Pharm Bull (Tokyo); 1997 Dec; 45(12):2125-8. PubMed ID: 9433785
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-HIV-1 peptides derived from partial amino acid sequences of CC-chemokine RANTES. Regulated upon activation, normal T-cell expressed and secreted.
    Nishiyama Y; Murakami T; Shikama S; Kurita K; Yamamoto N
    Bioorg Med Chem; 2002 Dec; 10(12):4113-7. PubMed ID: 12413865
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analogues of N-terminal truncated synthetic peptide fragments derived from RANTES inhibit HIV-1 infectivity.
    Ramnarine EJ; Devico AL; Vigil-Cruz SC
    Bioorg Med Chem Lett; 2006 Jan; 16(1):93-5. PubMed ID: 16236501
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhancement of anti-HIV-1 activity by hot spot evolution of RANTES-derived peptides.
    Secchi M; Longhi R; Vassena L; Sironi F; Grzesiek S; Lusso P; Vangelista L
    Chem Biol; 2012 Dec; 19(12):1579-88. PubMed ID: 23261601
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Variable sensitivity of CCR5-tropic human immunodeficiency virus type 1 isolates to inhibition by RANTES analogs.
    Torre VS; Marozsan AJ; Albright JL; Collins KR; Hartley O; Offord RE; Quiñones-Mateu ME; Arts EJ
    J Virol; 2000 May; 74(10):4868-76. PubMed ID: 10775626
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dissociation of the signalling and antiviral properties of SDF-1-derived small peptides.
    Heveker N; Montes M; Germeroth L; Amara A; Trautmann A; Alizon M; Schneider-Mergener J
    Curr Biol; 1998 Mar; 8(7):369-76. PubMed ID: 9545196
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Critical role of the N-loop and beta1-strand hydrophobic clusters of RANTES-derived peptides in anti-HIV activity.
    Vangelista L; Longhi R; Sironi F; Pavone V; Lusso P
    Biochem Biophys Res Commun; 2006 Dec; 351(3):664-8. PubMed ID: 17083916
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical evaluation of synthetic -2 RANTES as a candidate vaginal microbicide to target CCR5.
    Kish-Catalone TM; Lu W; Gallo RC; DeVico AL
    Antimicrob Agents Chemother; 2006 Apr; 50(4):1497-509. PubMed ID: 16569870
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural determinants of CCR5 recognition and HIV-1 blockade in RANTES.
    Nardese V; Longhi R; Polo S; Sironi F; Arcelloni C; Paroni R; DeSantis C; Sarmientos P; Rizzi M; Bolognesi M; Pavone V; Lusso P
    Nat Struct Biol; 2001 Jul; 8(7):611-5. PubMed ID: 11427892
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Highly potent HIV inhibition: engineering a key anti-HIV structure from PSC-RANTES into MIP-1 beta/CCL4.
    Gaertner H; Lebeau O; Borlat I; Cerini F; Dufour B; Kuenzi G; Melotti A; Fish RJ; Offord R; Springael JY; Parmentier M; Hartley O
    Protein Eng Des Sel; 2008 Feb; 21(2):65-72. PubMed ID: 18178567
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhancement of the HIV-1 inhibitory activity of RANTES by modification of the N-terminal region: dissociation from CCR5 activation.
    Polo S; Nardese V; De Santis C; Arcelloni C; Paroni R; Sironi F; Verani A; Rizzi M; Bolognesi M; Lusso P
    Eur J Immunol; 2000 Nov; 30(11):3190-8. PubMed ID: 11093134
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potent, broad-spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140.
    Trkola A; Ketas TJ; Nagashima KA; Zhao L; Cilliers T; Morris L; Moore JP; Maddon PJ; Olson WC
    J Virol; 2001 Jan; 75(2):579-88. PubMed ID: 11134270
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Total chemical synthesis and high-resolution crystal structure of the potent anti-HIV protein AOP-RANTES.
    Wilken J; Hoover D; Thompson DA; Barlow PN; McSparron H; Picard L; Wlodawer A; Lubkowski J; Kent SB
    Chem Biol; 1999 Jan; 6(1):43-51. PubMed ID: 9889151
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular engineering of RANTES peptide mimetics with potent anti-HIV-1 activity.
    Lusso P; Vangelista L; Cimbro R; Secchi M; Sironi F; Longhi R; Faiella M; Maglio O; Pavone V
    FASEB J; 2011 Apr; 25(4):1230-43. PubMed ID: 21199933
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peptide, peptidomimetic and small-molecule drug discovery targeting HIV-1 host-cell attachment and entry through gp120, gp41, CCR5 and CXCR4.
    Kazmierski WM; Kenakin TP; Gudmundsson KS
    Chem Biol Drug Des; 2006 Jan; 67(1):13-26. PubMed ID: 16492145
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Computational prediction of anti HIV-1 peptides and in vitro evaluation of anti HIV-1 activity of HIV-1 P24-derived peptides.
    Poorinmohammad N; Mohabatkar H; Behbahani M; Biria D
    J Pept Sci; 2015 Jan; 21(1):10-6. PubMed ID: 25407510
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Coreceptor usage and RANTES sensitivity of non-syncytium-inducing HIV-1 isolates obtained from patients with AIDS.
    Jansson M; Backström E; Björndal A; Holmberg V; Rossi P; Fenyö EM; Popovic M; Albert J; Wigzell H
    J Hum Virol; 1999; 2(6):325-38. PubMed ID: 10774549
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of RANTES/CCR1-mediated chemotaxis by cosalane and related compounds.
    Howard OM; Dong HF; Oppenheim JJ; Insaf S; Santhosh KC; Paul G; Cushman M
    Bioorg Med Chem Lett; 2001 Jan; 11(1):59-62. PubMed ID: 11140734
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peptide and non-peptide HIV fusion inhibitors.
    Jiang S; Zhao Q; Debnath AK
    Curr Pharm Des; 2002; 8(8):563-80. PubMed ID: 11945159
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.